Inbrija

RSS

levodopa

Authorised
This medicine is authorised for use in the European Union.

Overview

Inbrija is a medicine used to treat adults with Parkinson’s disease (a progressive brain disease that causes shaking and muscle stiffness and slows movement).

Inbrija is used to treat symptoms during ‘off’ periods (times when the patient has more difficulty moving about) that occur while the patient is taking their usual treatment of a combination of levodopa and an inhibitor of dopa-decarboxylase.

Inbrija contains the active substance levodopa.

This EPAR was last updated on 30/09/2019

Authorisation details

Product details
Name
Inbrija
Agency product number
EMEA/H/C/004786
Active substance
levodopa
International non-proprietary name (INN) or common name
levodopa
Therapeutic area (MeSH)
Parkinson Disease
Anatomical therapeutic chemical (ATC) code
N04BA01
Publication details
Marketing-authorisation holder
Acorda Therapeutics Ireland Limited
Date of issue of marketing authorisation valid throughout the European Union
19/09/2019
Contact address

10 Earlsfort Terrace
Dublin 2, D02 T380
Ireland

Product information

19/09/2019 Inbrija - EMEA/H/C/004786 -

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

ANTI-PARKINSON DRUGS

Therapeutic indication

Inbrija is indicated for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor.

Assessment history

How useful was this page?

Add your rating